Ascending enteric organisms
Escherichia coli and other Enterobacterales enter through the urethra or reflux infected urine into prostatic ducts, causing most acute cases.
Recognise acute bacterial prostatitis, distinguish sepsis and retention, obtain useful cultures and prescribe prostate-penetrating treatment with an explicit fourteen-day review.
Acute bacterial prostatitis is abrupt bacterial infection of prostate tissue, usually caused by enteric Gram-negative organisms entering through the urethra or refluxing infected urine into prostatic ducts.
Prostate penetration matters. Bladder-only agents such as nitrofurantoin do not achieve therapeutic tissue concentrations and are unsuitable even when a urine isolate appears susceptible.
Fluoroquinolones penetrate prostate tissue but carry strict safety restrictions. Use them only when other commonly recommended antibiotics are inappropriate after individual adverse-effect and interaction review.
Acute bacterial prostatitis is distinct from chronic bacterial prostatitis and chronic pelvic pain syndrome. Recurrent or prolonged symptoms need culture, anatomical and pain assessment rather than automatic repetition of an acute regimen.
Escherichia coli and other Enterobacterales enter through the urethra or reflux infected urine into prostatic ducts, causing most acute cases.
Biopsy, catheterisation, cystoscopy, urinary retention and prostatic enlargement facilitate bacterial entry and increase healthcare-associated resistance risk.
Gonorrhoea and chlamydia are less common causes but should be considered with urethritis, exposure history or epididymal symptoms.
Organisms enter prostatic ducts, replicate within glandular tissue and trigger intense neutrophilic inflammation, oedema and pelvic pain.
Inflammatory swelling compresses the prostatic urethra, causing weak flow, residual urine and sometimes complete painful retention.
Drug ionisation, protein binding and lipid solubility determine prostate exposure, making some bladder-active antibiotics clinically inadequate.
Persistent focal suppuration can become encapsulated, preventing cure with antibiotics alone and requiring image-guided or operative drainage.
Fever, rigors, malaise, dysuria, frequency and urgency with perineal, rectal, penile or low-back pain supports acute bacterial prostatitis.
Gentle rectal examination may find a tender boggy or swollen prostate, but absence does not exclude infection and forceful massage is unsafe.
Weak stream, painful inability to void and palpable bladder suggests oedema-related outlet obstruction requiring prompt urological assessment.
Persistent fever, bacteraemia or focal pelvic pain despite active therapy raises suspicion for a collection requiring imaging and drainage.
Cystitis produces dysuria and frequency without prominent fever, perineal pain, prostate tenderness or significant systemic illness.
Scrotal pain, epididymal swelling or urethral discharge suggests a sexual-health or enteric genital infection requiring targeted testing.
Pelvic pain lasting months with negative cultures and variable urinary or sexual symptoms is not managed as prolonged acute infection.
Persistent haematuria, weight loss, abnormal prostate findings or recurrent sterile urinary symptoms requires prompt urological cancer assessment.
Urethral discharge, new sexual exposure, epididymal pain or proctitis features should prompt STI testing alongside bacterial urine culture.
Ongoing bacterial suppuration produces persistent fever, pain and bacteraemia despite active treatment and often requires drainage.
Acute inflammatory oedema obstructs the urethra, causing painful bladder distension, renal injury and urgent drainage need.
A vascular inflamed gland can seed the bloodstream spontaneously or after manipulation, leading to organ dysfunction and shock.
Inadequate activity, resistant organisms or structural disease can lead to recurrent infection, chronic pain and voiding dysfunction.
NICE structures treatment as 14 days followed by review; only ongoing clinical need supports a further 14 days.
Forceful prostatic massage during acute infection can worsen pain and provoke bacteraemia and should not be performed.
Nitrofurantoin may test active in urine yet does not reach dependable prostate concentrations for acute prostatitis.
Acute retention requires urological input because inflamed obstructed anatomy and repeated instrumentation can cause trauma and bacteraemia.
Failure to defervesce on active therapy should trigger evaluation for prostatic abscess, resistance or another infection source.
Prostate-specific antigen can rise during acute inflammation and should not be used to diagnose infection or trigger premature cancer interpretation during the episode.
Do not use nitrofurantoin for acute bacterial prostatitis despite a susceptible urine report.
Do not perform vigorous prostate massage to obtain secretions during acute infection.
Do not prescribe a fluoroquinolone without applying current restrictions and explaining potentially persistent adverse effects.
Do not leave acute urinary retention for routine review; arrange prompt urological drainage assessment.
Do not continue long courses without reviewing culture, anatomical complications and alternative chronic pelvic pain syndromes.
Your practice draft is saved in this browser.
A stable adult with culture-supported acute bacterial prostatitis can take oral medicine and has no retention. A fluoroquinolone is appropriate after safety review. Which NICE regimen is correct?
National guidance is shown before implementation-dependent detail. Typical adult dose examples remain subject to patient factors, contraindications and the live BNF or specialist protocol. Source check completed 27 Aug 2026; clinical approval remains outstanding.
Editorial contact: Doctor’s Passport editorial team. Source-check date is separate from clinical approval. Report a content problem · Content changes
Follow MHRA restrictions; assess renal function, tendon, neurological, psychiatric, aortic, cardiac and glycaemic risk and interactions, and avoid in pregnancy.
Apply fluoroquinolone restrictions, dose adjustment and serious adverse-effect counselling; review QT prolongation, interacting medicines and previous resistant organisms.
Check renal function, potassium, folate status, resistance risk and interactions with methotrexate, warfarin, ACE inhibitors and spironolactone.
Use only under fluoroquinolone restrictions; adjust for renal impairment and review tendon, neurological, psychiatric, vascular, QT and glycaemic risks.